



Vigilancia de la Parálisis Flácida Aguda en las Américas

Vol. 33, No.29

Semana que termina el 21 de julio del 2018

Tabla No.1

Casos PFA esperados y reportados, 2018

| Sub región | País | Población <15 años* | Casos PFA esperados | Casos PFA reportados 2018/29 |
|--------------|--------------------|---------------------|---------------------|------------------------------|
| AND | BOL | 3,488,083 | 35 | 26 |
| | COL | 11,622,602 | 116 | 69 |
| | ECU | 4,705,464 | 47 | 10 |
| | PER | 8,786,980 | 88 | 48 |
| | VEN | 8,765,312 | 88 | 15 |
| BRA | BRA | 47,426,629 | 474 | 170 |
| CAP | CRI | 1,065,783 | 11 | 4 |
| | GTM | 6,032,750 | 60 | 22 |
| | HND | 3,221,178 | 32 | 26 |
| | NIC | 1,814,682 | 18 | 11 |
| | PAN | 1,073,291 | 11 | 10 |
| SLV | 1,625,466 | 16 | 28 | |
| CAR | CAR | 1,758,319 | 18 | 3 |
| LAC | CUB | 1,830,247 | 18 | 15 |
| | DOM | 3,155,763 | 32 | 5 |
| | HTI | 3,616,958 | 36 | 4 |
| MEX | MEX | 34,977,953 | 350 | 318 |
| NOA | CAN | 5,797,902 | 58 | 0 |
| | USA | 61,098,121 | NR | NR |
| SOC | ARG | 10,987,085 | 110 | 74 |
| | CHL | 3,603,758 | 36 | 29 |
| | PRY | 2,077,285 | 21 | 14 |
| | URY | 731,231 | 7 | 0 |
| Total | 229,262,842 | 1682 | 901 | |

Tabla No.2

Casos PFA bajo investigación (Todas las edades)

| País | Total 2017 | Acum. 2018 | Semana | | | | | | | | | | | | |
|--------------|------------|------------|------------|-----------|-----------|-----------|-----------|-----------|----------|----------|----------|-----|-----|--|--|
| | | | 1-21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | | | | |
| BOL | 0 | 12 | 7 | 1 | 1 | 2 | 0 | 0 | 1 | 0 | ... | ... | ... | | |
| COL | 0 | 23 | 13 | 3 | 2 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | | |
| ECU | 1 | 9 | 9 | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | | |
| PER | 0 | 19 | 7 | 1 | 3 | 4 | 1 | 3 | 0 | 0 | ... | ... | ... | | |
| VEN | 1 | 4 | 3 | 0 | 1 | 0 | 0 | ... | ... | ... | ... | ... | ... | | |
| BRA | 0 | 60 | 48 | 3 | 2 | 3 | 3 | 1 | 0 | 0 | ... | ... | ... | | |
| CRI | 0 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | |
| GTM | 1 | 12 | 11 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | |
| HND | 0 | 9 | 0 | 1 | 1 | 0 | 3 | 2 | 2 | 0 | 0 | 0 | 0 | | |
| NIC | 0 | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | | |
| PAN | 0 | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ... | | |
| SLV | 0 | 18 | 5 | 2 | 1 | 4 | 1 | 3 | 0 | 2 | 0 | 0 | 0 | | |
| CAR | 0 | 3 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | | |
| CUB | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | |
| DOM | 0 | 5 | 5 | 0 | 0 | 0 | ... | ... | ... | ... | ... | ... | ... | | |
| HTI | 2 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | |
| MEX | 0 | 18 | 4 | 0 | 2 | 2 | 3 | 3 | 2 | 2 | 0 | 0 | 0 | | |
| CAN | 0 | 0 | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | | |
| USA | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | | |
| ARG | 0 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ... | | |
| CHL | 0 | 15 | 11 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | | |
| PRY | 0 | 8 | 4 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | | |
| URY | 0 | 0 | 0 | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | | |
| Total | 5 | 236 | 144 | 13 | 15 | 20 | 18 | 14 | 6 | 5 | 1 | | | | |

* Datos reportados por países

NR - No reporta

... - Sin datos

Tabla No.3 Casos de polio confirmados y compatibles, e indicadores de vigilancia de PFA, 2018 y 2017

| Sub región | País | Polio 2018 | | Casos PFA e indicadores, últimas 52 semanas (2017/30 - 2018/29) | | | | | Polio 2017 | | Casos PFA e indicadores, 2017 (2017/1 - 2017/52) | | | | |
|----------------|----------|------------|-------------|---|-----------|-----------------|---------------------|--------------------|------------|------------|--|-------------|-----------------|---------------------|--------------------|
| | | Confirmado | Compatible | Casos | Tasa | % Inv. <48 hrs. | % muestra adecuada* | % unid. notifican. | Confirmado | Compatible | Casos | Tasa | % Inv. <48 hrs. | % muestra adecuada* | % unid. notifican. |
| AND | BOL | 0 | 0 | 39 | 1.12 | 72 | 79 | ... | 0 | 0 | 15 | 0.43 | 20 | 80 | ... |
| | COL | 0 | 0 | 148 | 1.27 | 61 | 82 | 96 | 0 | 0 | 156 | 1.34 | 60 | 83 | 95 |
| | ECU | 0 | 0 | 22 | 0.47 | 100 | 77 | ... | 0 | 0 | 38 | 0.81 | 97 | 84 | ... |
| | PER | 0 | 0 | 68 | 0.77 | 91 | 84 | 15 | 0 | 0 | 52 | 0.59 | 73 | 71 | 52 |
| | VEN | 0 | 0 | 46 | 0.52 | 89 | 61 | ... | 0 | 4 | 84 | 0.96 | 87 | 80 | 84 |
| BRA | BRA | 0 | 0 | 364 | 0.77 | 99 | 64 | 79 | 0 | 1 | 486 | 1.02 | 99 | 69 | 29 |
| CAP | CRI | 0 | 0 | 9 | 0.84 | 78 | 100 | ... | 0 | 0 | 27 | 2.53 | 78 | 89 | ... |
| | GTM | 0 | 0 | 42 | 0.70 | 7 | 74 | 91 | 0 | 0 | 46 | 0.76 | ... | 72 | 83 |
| | HND | 0 | 0 | 44 | 1.37 | 59 | 93 | 90 | 0 | 0 | 48 | 1.49 | 48 | 92 | 90 |
| | NIC | 0 | 0 | 23 | 1.27 | 91 | 96 | 100 | 0 | 0 | 19 | 1.05 | 74 | 95 | 99 |
| | PAN | 0 | 0 | 19 | 1.77 | 68 | 84 | 87 | 0 | 0 | 22 | 2.05 | 50 | 95 | 84 |
| SLV | 0 | 0 | 42 | 2.58 | 21 | 88 | 30 | 0 | 0 | 41 | 2.52 | 34 | 93 | 32 | |
| CAR | CAR | 0 | 0 | 3 | 0.17 | 33 | 67 | 78 | 0 | 0 | 6 | 0.34 | 83 | 100 | 72 |
| LAC | CUB | 0 | 0 | 21 | 1.15 | 67 | 71 | 100 | 0 | 0 | 15 | 0.82 | ... | ... | 100 |
| | DOM | 0 | 0 | 13 | 0.41 | ... | 92 | ... | 0 | 0 | 15 | 0.48 | ... | 87 | ... |
| | HTI | 0 | 0 | 7 | 0.19 | 100 | 43 | 68 | 0 | 0 | 8 | 0.22 | 63 | 50 | 46 |
| MEX | MEX | 0 | 0 | 610 | 1.74 | 99 | 86 | 96 | 0 | 0 | 569 | 1.63 | 99 | 83 | ... |
| NOA | CAN | 0 | 0 | 3 | 0.05 | ... | ... | ... | 0 | 0 | 19 | 0.33 | ... | 26 | ... |
| | USA | 0 | 0 | NR | NR | NR | NR | NR | 0 | 0 | NR | NR | NR | NR | NR |
| SOC | ARG | 0 | 0 | 180 | 1.64 | 48 | 82 | 82 | 0 | 0 | 205 | 1.87 | 42 | 79 | 81 |
| | CHL | 0 | 0 | 56 | 1.55 | 88 | 61 | 76 | 0 | 0 | 69 | 1.91 | 97 | 71 | 74 |
| | PRY | 0 | 0 | 28 | 1.35 | 89 | 100 | 92 | 0 | 0 | 30 | 1.44 | 87 | 93 | 91 |
| | URY | 0 | 0 | 3 | 0.41 | 100 | ... | ... | 0 | 0 | 4 | 0.55 | 100 | ... | ... |
| Total § | 0 | 0 | 1790 | 1.06 | 82 | 79 | - | | 0 | 5 | 1974 | 1.17 | 79 | 78 | - |

+ Tomado dentro de los primeros 14 días del inicio de parálisis

... - Sin datos

CAR incluye informes de países miembros de CARPHA

§ Excluyendo a EUA

NR - No reportando

Sólo se incluyen datos de casos de PFA en menores de 15 años en tablas 1 y 2

El boletín de vigilancia de la poliomielitis se encuentra en: www.paho.org/inmunizacion/BoletinPolio



Tabla No.1
Resultados e indicadores de aislamiento viral, últimas 52 semanas
Semanas epidemiológicas 2017/30 - 2018/29

| Lab. | País | Número de muestras de casos de PFA | Prueba de aislamiento viral | | | | | | | | | | Tiempo para el resultado de aislamiento | | | |
|-----------------------------|------|------------------------------------|-----------------------------|-------------------|-------------------|------------------|-------------------|-----------|-------------|----------|------------|----------|---|------------------------------|---|---------------------------|
| | | | Pendiente de resultados | | | Con resultados | | | | | | | % muestras positivas de NPEV | Total muestras con resultado | Total con fecha de recepción y de resultado | % con resultado ≤ 14 días |
| | | | Aún no en lab. | Recibido ≤14 días | Recibido >14 días | Sólo polio virus | Poliovirus y NPEV | Sólo NPEV | Negativo | Otros | Inadecuado | | | | | |
| CAR | ATG | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | DOM | 12 | 4 | 0 | 0 | 0 | 0 | 1 | 7 | 0 | 0 | 13 | 8 | 8 | 100 | |
| | GUY | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 100 | |
| | HND | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 0 | 0 | 0 | 18 | 18 | 100 | |
| | HTI | 7 | 1 | 0 | 1 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 5 | 3 | 33 | |
| | NIC | 26 | 3 | 0 | 0 | 0 | 0 | 0 | 4 | 19 | 0 | 0 | 17 | 23 | 23 | 91 |
| PAN | 21 | 4 | 0 | 1 | 0 | 0 | 0 | 1 | 15 | 0 | 0 | 6 | 16 | 16 | 94 | |
| CDC | GTM | 41 | 13 | 0 | 1 | 1 | 0 | 2 | 24 | 0 | 0 | 11 | 27 | 11 | 0 | |
| | HND | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 17 | 0 | 0 | 0 | 17 | 14 | 100 | |
| | PRY | 28 | 8 | 0 | 0 | 0 | 0 | 2 | 18 | 0 | 0 | 10 | 20 | 20 | 65 | |
| | SLV | 42 | 0 | 2 | 9 | 0 | 0 | 0 | 31 | 0 | 0 | 0 | 31 | 31 | 0 | |
| FIO | BRA | 242 | 14 | 0 | 7 | 2 | 0 | 3 | 216 | 0 | 0 | 2 | 221 | 220 | 57 | |
| | PER | 43 | 6 | 0 | 1 | 0 | 0 | 2 | 34 | 0 | 0 | 6 | 36 | 36 | 36 | |
| IEC | BRA | 48 | 3 | 0 | 0 | 0 | 0 | 4 | 41 | 0 | 0 | 9 | 45 | 44 | 75 | |
| INDRE | MEX | 548 | 0 | 22 | 4 | 1 | 0 | 32 | 490 | 0 | 0 | 6 | 523 | 523 | 98 | |
| INH | VEN | 39 | 2 | 0 | 2 | 1 | 0 | 7 | 27 | 0 | 0 | 23 | 35 | 35 | 83 | |
| INS | COL | 143 | 0 | 0 | 4 | 0 | 0 | 7 | 132 | 0 | 0 | 5 | 139 | 139 | 94 | |
| | CRI | 12 | 7 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 5 | 5 | 100 | |
| | ECU | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 17 | 0 | 0 | 0 | 17 | 17 | 100 | |
| | VEN | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 100 | |
| IPK | CUB | 15 | 0 | 0 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| ISP | CHL | 43 | 0 | 0 | 0 | 0 | 0 | 4 | 39 | 0 | 0 | 9 | 43 | 43 | 93 | |
| MAL | ARG | 164 | 0 | 0 | 1 | 0 | 0 | 9 | 154 | 0 | 0 | 6 | 163 | 160 | 80 | |
| | BOL | 39 | 12 | 0 | 0 | 0 | 0 | 2 | 25 | 0 | 0 | 7 | 27 | 27 | 100 | |
| (sin nombre de laboratorio) | DOM | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | ECU | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | GTM | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | HND | 11 | 9 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | |
| | PER | 18 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total | | 1608 | 113 | 24 | 47 | 5 | 0 | 80 | 1337 | 0 | 0 | 6 | 1422 | 1395 | 83 | |

... Sin datos

Sólo se incluyen muestras de heces de casos de PFA en menores de 15 años

Tabla No.2
Estado de pruebas de diferenciación intratípica (ITD) para muestras con aislamiento de poliovirus, últimas 52 semanas
Semanas epidemiológicas 2017/30 - 2018/29

| Lab. | País | Número de poliovirus aislados | Resultado de diferenciación intratípica de poliovirus | | | | | | | | | Indicadores ITD | | | | | |
|--------------|------|-------------------------------|---|----------|----------|----------|----------|----------|----------|----------|----------|----------------------------|--------------------------------------|---|--|---|---|
| | | | Sabin | | | VDPV | | | Salvaje | | | Pendiente de resultado ITD | Número de muestras con resultado ITD | Resultado ITD con fechas de recepción o detección y resultado | % con resultado ITD ≤ 7 días de la recepción o detección | % con resultado ITD ≤ 45 días del inicio de parálisis | % con resultado ITD ≤ 60 días del inicio de parálisis |
| | | | P1 | P2 | P3 | P1 | P2 | P3 | P1 | P2 | P3 | | | | | | |
| CDC | GTM | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| FIO | BRA | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 100 | 100 | 100 |
| INDRE | MEX | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 100 | 100 | 100 |
| INH | VEN | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 100 | 100 | 100 |
| INS | COL | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 100 | 100 | 100 |
| Total | | 5 | 4 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 83 | 83 | 83 |